Literature DB >> 17189897

Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity.

Parag K Shah1, V Narendran, Khaled A Tawansy, A Raghuram, Kalpana Narendran.   

Abstract

Aggressive posterior retinopathy of prematurity (formerly known as fulminate/type II/rush disease) occurs in zone 1 or posterior zone 2. Treatment involves extensive near confluent laser ablation of a large area of avascular retina. Anterior segment ischemia is a rare complication that can occur due to injury to the long posterior ciliary arteries in the horizontal meridians during aggressive posterior laser treatment. The outcome of this rare complication is very poor. This case describes a favorable outcome of intravitreal injection of bevacizumab (Avastin) in a case of anterior segment ischemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17189897     DOI: 10.4103/0301-4738.29505

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


  28 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.

Authors:  Shigeru Honda; Hiroaki Hirabayashi; Yasutomo Tsukahara; Akira Negi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-03-05       Impact factor: 3.117

3.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

4.  Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report.

Authors:  Hae Jung Sun; Kyung Seek Choi; Sung Jin Lee
Journal:  Jpn J Ophthalmol       Date:  2012-07-28       Impact factor: 2.447

5.  Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.

Authors:  J Fernando Arevalo; Juan G Sanchez; Jans Fromow-Guerra; Lihteh Wu; Maria H Berrocal; Michel E Farah; Jose Cardillo; Francisco J Rodríguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-03       Impact factor: 3.117

6.  Intravitreal cysticercosis presenting as neovascular glaucoma.

Authors:  Dhanashree Ratra; Chekitaan Phogat; Maneesh Singh; Nikhil S Choudhari
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

7.  Intravitreal bevacizumab: an analysis of the evidence.

Authors:  Derrick P Smit; David Meyer
Journal:  Clin Ophthalmol       Date:  2007-09

Review 8.  The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment.

Authors:  Lois E Smith; Anna-Lena Hard; Ann Hellström
Journal:  Clin Perinatol       Date:  2013-06       Impact factor: 3.430

Review 9.  The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.

Authors:  Nazimul Hussain; Yashoda Ghanekar; Inderjeet Kaur
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

Review 10.  The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration.

Authors:  Rajvardhan Azad; Parijat Chandra; Ritesh Gupta
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.